Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy
Open accessThe DOI matches its Crossref record; 69 of the 70 references it cites were found in a registry or an index.
Abstract
The type 1 insulin-like growth factor receptor (IGF-1R) tyrosine kinase is an important mediator of the protumorigenic effects of IGF-I/II, and inhibitors of IGF-1R signaling are currently being tested in clinical cancer trials aiming to assess the utility of this receptor as a therapeutic target. Despite mounting evidence that the highly homologous insulin receptor (IR) can also convey protumorigenic signals, its direct role in cancer progression has not been genetically defined in vivo, and it remains unclear whether such a role for IR signaling could compromise the efficacy of selective IGF-1R targeting strategies. A transgenic mouse model of pancreatic neuroendocrine carcinogenesis engages the IGF signaling pathway, as revealed by its dependence on IGF-II and by accelerated malignant progression upon IGF-1R overexpression. Surprisingly, preclinical trials with an inhibitory monoclonal antibody to IGF-1R did not significantly impact tumor growth, prompting us to investigate the involvement of IR. The levels of IR were found to be significantly up-regulated during multistep progression from hyperplastic lesions to islet tumors. Its functional involvement was revealed by genetic disruption of the IR gene in the oncogene-expressing pancreatic β cells, which resulted in reduced tumor burden accompanied by increased apoptosis. Notably, the IR knockout tumors now exhibited sensitivity to anti–IGF-1R therapy; similarly, high IR to IGF-1R ratios demonstrably conveyed resistance to IGF-1R inhibition in human breast cancer cells. The results predict that elevated IR signaling before and after treatment will respectively manifest intrinsic and adaptive resistance to anti–IGF-1R therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Prior studies with KRAS G12C , RAF, and MEK inhibitors indicated that blockade of KRAS-dependent signaling activated a transcriptional program suppressing DUSP , SPRY , and ETV family genes which cooperate to mediate increased signaling flux though RTK, SOS, and MEK/ERK family members resulting in conditional bypass dependence on KRAS [4, 32-34].”
From Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor (2022) · cites this paper as [33]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pàez-Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Viñals, F., Inoue, M., Bergers, G., Hanahan, D., & Casanovas, O. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.027 · Cited by 2,339
Self-citationInsulin and insulin-like growth factor signalling in neoplasia
Pollak, M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2536 · Cited by 2,059
Ullrich, A., Gray, A., Tam, A. W., Yang-Feng, T., Tsubokawa, M., Collins, C., Henzel, W., Le Bon, T., Kathuria, S., & Chen, E. (1986) · The EMBO Journal · doi:10.1002/j.1460-2075.1986.tb04528.x · Cited by 1,844
Casanovas, O., Hicklin, D. J., Bergers, G., & Hanahan, D. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.005 · Cited by 1,621
Self-citationInsulin-like growth factors and neoplasia
Pollak, M. N., Schernhammer, E. S., & Hankinson, S. E. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1387 · Cited by 1,463
Postic, C., Shiota, M., Niswender, K. D., Jetton, T. L., Chen, Y., Moates, J. M., Shelton, K. D., Lindner, J., Cherrington, A. D., & Magnuson, M. A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.1.305 · Cited by 1,302
Hanahan, D. (1985) · Nature · doi:10.1038/315115a0 · Cited by 1,281
Self-citationGene Expression Profiles in Normal and Cancer Cells
Zhang, L., Zhou, W., Velculescu, V. E., Kern, S. E., Hruban, R. H., Hamilton, S. R., Vogelstein, B., & Kinzler, K. W. (1997) · Science · doi:10.1126/science.276.5316.1268 · Cited by 1,184
Brüning, J. C., Michael, M. D., Winnay, J. N., Hayashi, T., Hörsch, D., Accili, D., Goodyear, L. J., & Kahn, C. R. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80155-0 · Cited by 1,182
Self-citationKulkarni, R. N., Brüning, J. C., Winnay, J. N., Postic, C., Magnuson, M. A., & Kahn, C. R. (1999) · Cell · doi:10.1016/s0092-8674(00)80546-2 · Cited by 1,148
Self-citationAdvances in Male Contraception
Page, S. T., Amory, J. K., & Bremner, W. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0041 · Cited by 1,134
Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution
Shah, S. P., Morin, R. D., Khattra, J., Prentice, L., Pugh, T., Burleigh, A., Delaney, A., Gelmon, K., Guliany, R., Senz, J., et al. (2009) · Nature · doi:10.1038/nature08489 · Cited by 1,069
The Role of the IGF System in Cancer Growth and Metastasis: Overview and Recent Insights
Samani, A. A., Yakar, S., LeRoith, D., & Brodt, P. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0001 · Cited by 1,005
Effects of Angiogenesis Inhibitors on Multistage Carcinogenesis in Mice
Bergers, G., Javaherian, K., Lo, K.-M., Folkman, J., & Hanahan, D. (1999) · Science · doi:10.1126/science.284.5415.808 · Cited by 988
Self-citationFrasca, F., Pandini, G., Scalia, P., Sciacca, L., Mineo, R., Costantino, A., Goldfine, I. D., Belfiore, A., & Vigneri, R. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.5.3278 · Cited by 902
The Effects of Insulin-Like Growth Factors on Tumorigenesis and Neoplastic Growth
Khandwala, H. M., McCutcheon, I. E., Flyvbjerg, A., & Friend, K. E. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.3.0399 · Cited by 843
Loss of IGF2 Imprinting: A Potential Marker of Colorectal Cancer Risk
Cui, H., Cruz-Correa, M., Giardiello, F. M., Hutcheon, D. F., Kafonek, D. R., Brandenburg, S., Wu, Y., He, X., Powe, N. R., & Feinberg, A. P. (2003) · Science · doi:10.1126/science.1080902 · Cited by 735
The IGF‐1 receptor in cancer biology
Baserga, R., Peruzzi, F., & Reiss, K. (2003) · International Journal of Cancer · doi:10.1002/ijc.11487 · Cited by 642
Metabolic syndrome, hyperinsulinemia, and colon cancer: a review
Giovannucci, E. (2007) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/86.3.836s · Cited by 531
Pandini, G., Frasca, F., Mineo, R., Sciacca, L., Vigneri, R., & Belfiore, A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202766200 · Cited by 500
Hormones and mammary carcinogenesis in mice, rats, and humans: a unifying hypothesis.
Nandi, S., Guzman, R. C., & Yang, J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.9.3650 · Cited by 422
The role of insulin receptors and IGF-I receptors in cancer and other diseases
Frasca, F., Pandini, G., Sciacca, L., Pezzino, V., Squatrito, S., Belfiore, A., & Vigneri, R. (2008) · Archives of Physiology and Biochemistry · doi:10.1080/13813450801969715 · Cited by 410
A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis
Christofori, G., Naik, P., & Hanahan, D. (1994) · Nature · doi:10.1038/369414a0 · Cited by 390
Self-citationBurtrum, D. B., Zhu, Z., Lu, D., Anderson, D. M., Prewett, M. C., PEREIRA, D. S., Bassi, R., Abdullah, R., Hooper, A. T., Koo, H., et al. (2003) · PubMed · Cited by 352
Self-citationHyper-insulinaemia and cancer, meta-analyses of epidemiological studies
Pisani, P. (2008) · Archives of Physiology and Biochemistry · doi:10.1080/13813450801954451 · Cited by 329
Phosphatidylinositol-3-OH Kinase or RAS Pathway Mutations in Human Breast Cancer Cell Lines
Hollestelle, A., Elstrodt, F., Nagel, J. H. A., Kallemeijn, W. W., & Schutte, M. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0263 · Cited by 320
The IGF system and breast cancer.
Sachdev, D., & Yee, D. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080197 · Cited by 314
IGF1R signalling and its inhibition
Riedemann, J., & Macaulay, V. M. (2006) · Endocrine-Related Cancer · doi:10.1677/erc.1.01280 · Cited by 301
Sciacca, L., Costantino, A., Pandini, G., Mineo, R., Frasca, F., Scalia, P., Sbraccia, P., Goldfine, I. D., Vigneri, R., & Belfiore, A. (1999) · Oncogene · doi:10.1038/sj.onc.1202600 · Cited by 288
Novosyadlyy, R., Lann, D. E., Vijayakumar, A., Rowzee, A., Lazzarino, D. A., Fierz, Y., Carboni, J. M., Gottardis, M. M., Pennisi, P. A., Molinolo, A. A., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2141 · Cited by 282
BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR
Carboni, J. M., Wittman, M., Yang, Z., Lee, F., Greer, A., Hurlburt, W., Hillerman, S., Cao, C., Cantor, G. H., Dell-John, J., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0499 · Cited by 280
Dunn, S. E., Ehrlich, M., Sharp, N., Krzysztof Reiss, F., Solomon, G., Hawkins, R., Baserga, R., & Barrett, J. C. (1998) · PubMed · Cited by 279
Papa, V., Gliozzo, B., Gm, C., McGuire, W. L., Moore, D. H., Fujita‐Yamaguchi, Y., Vigneri, R., Goldfine, I. D., & PEZZINO, V. (1993) · PubMed · Cited by 276
Gualberto, A., & Pollak, M. (2009) · Oncogene · doi:10.1038/onc.2009.172 · Cited by 274
Lopez, T., & Hanahan, D. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00055-7 · Cited by 268
Self-citationThe Role of Insulin Receptor Isoforms and Hybrid Insulin/IGF-I Receptors in Human Cancer
Belfiore, A. (2007) · Current Pharmaceutical Design · doi:10.2174/138161207780249173 · Cited by 252
Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas
Ouban, A., Muraca, P., Yeatman, T., & Coppola, D. (2003) · Human Pathology · doi:10.1016/s0046-8177(03)00291-0 · Cited by 251
The Use of Targeted Mouse Models for Preclinical Testing of Novel Cancer Therapeutics
Olive, K. P., & Tuveson, D. A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0436 · Cited by 244
Vella, V. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.1.245 · Cited by 239
Insulin receptor expression by human prostate cancers
Cox, M. E., Gleave, M. E., Zakikhani, M., Bell, R. H., Piura, E., Vickers, E., Cunningham, M., Larsson, O., Fazli, L., & Pollak, M. (2009) · The Prostate · doi:10.1002/pros.20852 · Cited by 223
Hormone responsive human breast cancer in long-term tissue culture: effect of insulin.
Osborne, C. K., Bolan, G., Monaco, M. E., & Lippman, M. E. (1976) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.73.12.4536 · Cited by 221
Insulin receptor expression and function in human breast cancer cell lines.
Milazzo, G., Giorgino, F., Damante, G., Sung, C., Stampfer, M. R., Vigneri, R., Goldfine, I. D., & Belfiore, A. (1992) · PubMed · Cited by 206
Soos, M. A., Whittaker, J., Lammers, R., Ullrich, A., & Siddle, K. (1990) · Biochemical Journal · doi:10.1042/bj2700383 · Cited by 201
Mitogenic properties of insulin and insulin analogues mediated by the insulin receptor
Ish-Shalom, D., Christoffersen, C. T., Vorwerk, P., Sacerdoti-Sierra, N., Shymko, R. M., Naor, D., & Meyts, P. D. (1997) · Diabetologia · doi:10.1007/s001250051393 · Cited by 193
Venkateswaran, V., Haddad, A. Q., Fleshner, N. E., Fan, R., Sugar, L. M., Nam, R., Klotz, L. H., & Pollak, M. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm231 · Cited by 182
(1981) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/67.1.51 · Cited by 180
Bartucci, M., Morelli, C., Mauro, L., Andò, S., & Surmacz, E. (2001) · PubMed · Cited by 172
Gannon, M., Shiota, C., Postic, C., Wright, C. V. E., & Magnuson, M. (2000) · genesis · doi:10.1002/(sici)1526-968x(200002)26:2<139::aid-gene12>3.0.co;2-7 · Cited by 169
Huang, F., Greer, A., Hurlburt, W., Han, X., Hafezi, R., Wittenberg, G. M., Reeves, K., Chen, J., Robinson, D., Li, A., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-0835 · Cited by 164
Zhang, H., Pelzer, A. M., Kiang, D. T., & Yee, D. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1712 · Cited by 162
Desbois-Mouthon, C., Baron, A., Blivet-Van Eggelpoël, M.-J., Fartoux, L., Venot, C., Bladt, F., Housset, C., & Rosmorduc, O. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2980 · Cited by 157
Kalli, K. R., Falowo, O. I., Bale, L. K., Zschunke, M. A., Roche, P. C., & Conover, C. A. (2002) · Endocrinology · doi:10.1210/en.2001-211408 · Cited by 153
IGF and Insulin Receptor Signaling in Breast Cancer
Belfiore, A., & Frasca, F. (2008) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-008-9099-z · Cited by 151
Heuson, J.-C., & Legros, N. (1972) · PubMed · Cited by 151
Inhibition of cancer cell proliferation and metastasis by insulin receptor downregulation
Zhang, H., Fagan, D. H., Zeng, X., Freeman, K. T., Sachdev, D., & Yee, D. (2010) · Oncogene · doi:10.1038/onc.2010.17 · Cited by 130
Avnet, S., Sciacca, L., Salerno, M., Gancitano, G., Cassarino, M. F., Longhi, A., Zakikhani, M., Carboni, J. M., Gottardis, M., Giunti, A., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2645 · Cited by 102
Igf1r as a therapeutic target in a mouse model of basal-like breast cancer
Klinakis, A., Szabolcs, M., Chen, G., Xuan, S., Hibshoosh, H., & Efstratiadis, A. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810221106 · Cited by 100
Feng, Y., Zhu, Z., Xiao, X., Choudhry, V., Barrett, J. C., & Dimitrov, D. S. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0252 · Cited by 92
Zha, J., O'Brien, C. L., Savage, H. M., Huw, L., Zhong, F., Berry, L., Phillips, G. D. L., Luis, E., Cavet, G., Hu, X., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0381 · Cited by 86
Benoliel, A., Kahn‐Perlès, B., Imbert, J., & Verrando, P. (1997) · Journal of Cell Science · doi:10.1242/jcs.110.17.2089 · Cited by 79
Insulin, insulin-like growth factors, insulin resistance, and neoplasia
Pollak, M. (2007) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/86.3.820s · Cited by 78
Harnessing preclinical mouse models to inform human clinical cancer trials
Gutmann, D. H., Hunter‐Schaedle, K., & Shannon, K. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28271 · Cited by 72
Samani, A. A., & Brodt, P. (2001) · Surgical Oncology Clinics of North America · doi:10.1016/s1055-3207(18)30066-8 · Cited by 70
Vigneri, P. G., Frasca, F., Sciacca, L., Frittitta, L., & Vigneri, R. (2006) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2005.10.013 · Cited by 61
IGF2 loss of imprinting: a potential heritable risk factor for colorectal cancer☆
Jirtle, R. L. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.02.026 · Cited by 46
The insulin receptor as a transmitter of a mitogenic signal in Chinese hamster ovary CHO-K1 cells.
Mamounas, M. J., Gervin, D. B., & Englesberg, E. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.23.9294 · Cited by 36
Nolan-Stevaux, O., Truitt, M. C., Pahler, J. C., Olson, P., Guinto, C., Lee, D. C., & Hanahan, D. (2010) · Genes & Cancer · doi:10.1177/1947601909358722 · Cited by 31
Self-citationPrince, S., Foulstone, E. J., Zaccheo, O., Williams, C., & Hassan, A. B. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0509 · Cited by 30
Naik, P., Christofori, G., & Hanahan, D. (1994) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.1994.059.01.051 · Cited by 19
Self-citation
Research works printed but not linked: 2
- 10.1210/jcem.87.1.8142 · doi:10.1210/jcem.87.1.8142 · Paper page
- SM Shafie, FH Grantham, Role of hormones in the growth and regression of human breast cancer cells (MCF-7) transplanted into athymic nude mice. J Natl Cancer Inst 67, 51–56 (1981).
Cited by
The insulin and insulin-like growth factor receptor family in neoplasia: an update
Pollak, M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3215 · Cited by 1,116
Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies
Ben, Q., Xu, M., Ning, X., Liu, J., Hong, S., Huang, W., Zhang, H., & Li, Z. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.03.003 · Cited by 685
Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor
Hallin, J., Bowcut, V., Calinisan, A., Briere, D. M., Hargis, L., Engstrom, L. D., Laguer, J., Medwid, J., Vanderpool, D., Lifset, E., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02007-7 · Cited by 553
Insulin Receptor Isoforms in Physiology and Disease: An Updated View
Belfiore, A., Malaguarnera, R., Vella, V., Lawrence, M. C., Sciacca, L., Frasca, F., Morrione, A., & Vigneri, R. (2017) · Endocrine Reviews · doi:10.1210/er.2017-00073 · Cited by 375
Minireview: IGF, Insulin, and Cancer
Gallagher, E. J., & LeRoith, D. (2011) · Endocrinology · doi:10.1210/en.2011-0231 · Cited by 349
Metadata
- Authors
- Ulanet, D. B., Ludwig, D. L., Kahn, C. R., & Hanahan, D.
- Affiliations
- University of California, San Francisco (US)
- ImClone Systems, New York, NY 10014; and
- Joslin Diabetes Center (US)
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2010-05-10
- Volume
- 107
- Issue
- 24
- Pages
- 10791-10798
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2890766
- OpenAlex
- W2005890897
- Cited by
- 235
- References
- 70
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 3 · 2023: 11 · 2022: 12 · 2021: 11 · 2020: 15 · 2019: 13 · 2018: 6 · 2017: 18 · 2016: 18 · 2015: 18 · 2014: 19 · 2013: 23 · 2012: 25
- FWCI
- 21.00
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion, cc-by-nc-nd)
- Funders
- A.P. Giannini Foundation
- Joslin Diabetes Center
- Giannini Foundation of Agricultural Economics
- Fondation pour la Recherche Médicale
- University of California, San Francisco
- National Cancer Institute
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Keywords
- insulin receptor, IGF-1 receptor, IGF signaling, tumor progression, pancreatic neuroendocrine carcinoma, pancreatic beta cells, monoclonal antibody therapy, breast cancer, apoptosis, insulin-like growth factor II, receptor tyrosine kinase signaling
- MeSH terms
- Animals, Antibodies, Monoclonal, Breast Neoplasms, Female, Humans, Mice, Inbred C57BL, Mice, Transgenic, Neoplasms, Experimental, Pancreatic Neoplasms, Receptor, Insulin, Signal Transduction, Receptor, IGF Type 1, Receptor, IGF Type 2, Mice, Knockout, Neuroendocrine Tumors, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.